Well-Differentiated Liposarcoma (WDLS)

Overview

Well-differentiated liposarcoma (WDLS) is the most common and least aggressive subtype of liposarcoma, classified under Soft Tissue Sarcoma in OncoTree (parent: LIPO). It is characterized by MDM2 and CDK4 gene amplification at chromosome 12q13–15 and is locally aggressive but does not metastasize in its pure form. When it dedifferentiates it becomes dedifferentiated liposarcoma (DDLS), a high-grade malignancy.

Cohorts in the corpus

  • sarcoma_ucla_2024: SARC0120 was a WDLS specimen profiled in the UCLA PDTO biobank. MDM2 amplification was confirmed by FISH in both the parent tumor and the organoid, demonstrating genomic fidelity of the PDTO model (194 specimens from 126 patients, Feb 2018–May 2022). PMID:39305899

Recurrent alterations

  • MDM2: amplification confirmed by FISH in SARC0120 WDLS parent tumor and matched PDTO; canonical driver in WDLS/DDLS. PMID:39305899
  • CDK4: co-amplified with MDM2 at 12q13–15 in the vast majority of WDLS; cited as motivation for palbociclib testing. PMID:39305899

Subtypes

  • Well-differentiated liposarcoma (WDLS; locally aggressive, no metastasis)
  • Dedifferentiated liposarcoma (DDLS; arises from WDLS, high-grade, metastatic potential)

Therapeutic landscape

  • palbociclib: CDK4/6 inhibitor; CDK4 amplification in WDLS motivates testing. Evaluated across the UCLA sarcoma PDTO panel. PMID:39305899
  • MDM2 inhibitors (e.g., milademetan): under clinical investigation for MDM2-amplified liposarcoma; not specifically reported in this study.
  • PDTO screening identified ≥1 FDA-approved or NCCN-recommended regimen for 59% of sarcoma samples overall. PMID:39305899

Sources

  • PMID:39305899 — Al Shihabi et al. Cell Stem Cell 2024. UCLA sarcoma PDTO drug-sensitivity landscape.

This page was processed by crosslinker on 2026-05-04.